NEW YORK: Novel compounds showing early promise for Alzheimer’s disease (AD) target multiple disease-related proteins and may have benefits beyond AD, according to research presented here at the Alzheimer’s Association International Conference (AAIC) 2015.
Alzheimer’s is a complex disease that has been hard to tackle with the “one target, one treatment” approach, Maria Carrillo, PhD, chief science officer for the Alzheimer’s Association, said in statement.
“Fortunately, we’re beginning to see some very exciting early results at AAIC 2015 of a new treatment approach that targets common components of all the Alzheimer’s proteins, which also are common to other diseases that cause dementia. If these results can be shown in people, this strategy could eventually have benefit not just in Alzheimer’s but for other neurodegenerative diseases,” she noted…